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Antimicrobial treatment is often indicated to neutropenic patients. Although renal failure
is  a common complication of many antibiotics, no information could be found in the liter-
ature deﬁning which are the best screening criteria for detecting renal injury. In this paper,
the  authors aim to assess the progress to renal failure in neutropenic patients on antimi-
crobial  use and to compare different diagnostic criteria of renal failure in association to
antimicrobial  agents used. This is a cohort study conducted from February to August 2006
at  the Hospital das Clínicas of the Universidade Federal de Minas Gerais, which included
patients  with neutropenia and antimicrobial therapy for the treatment of Healthcare Asso-
ciated  Infections notiﬁed by the Hospital Infection Control Committee. Renal injury has
ensued  in 25% of patients and no statistical difference between distinct criteria for renal
injury  was observed. Association of greater number of antimicrobials was associated withrenal  impairment. Time required for renal injury was independent of the antimicrobial reg-
imen used, but mortality among patients with renal injury was higher when compared to
those who had preserved renal function.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDeutropenia is a prevalent complication in immunocompro-
ised patients and it is associated with high costs and high
orbidity  and mortality.1 It is estimated that the incidence
f  hospitalization for neutropenic patients is 60,000 cases per
ear  in the United States and the average total cost of hospi-
alization  is greater than US$ 20,000 per case.2Neutropenia increases the risk of infection, but early and
mpirical  use of antibiotics according to international guide-
ines  is a practice that has shown to reduce mortality.1,3
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Este é um artigo Open Access sob a licençaHowever, antimicrobial agents are associated to side-effects
that  lead to therapy change or drugs discontinuation.4
One of the most fearful side effects of antibiotics is nephro-
toxicity. Unfortunately, guidelines for the management of
neutropenic  patients include several medications and their
associations  can cause kidney damage.1,5Belo Horizonte, MG, 31130-110, Brazil.
It is estimated that, considering critically ill patients, acute
renal  failure (ARF) is associated with mortality rates exceed-
ing  50%, despite the availability of appropriate care and
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hemodialysis.6 Among patients who  develop chronic kidney
disease  mortality is also high. The survival rate of dialysis
patients along one, two and ﬁve years is about 80, 65, and 34%,
respectively.7
Although the number of neutropenic patients is increas-
ing  and renal injury in this group is a common complication,
no  information could be found in the literature deﬁning
which are the best screening criteria for detecting renal
injury.
In  this brief communication, the authors aim to assess
the  progress to renal failure in neutropenic patients on
antimicrobial use and compare different diagnostic criteria
of  renal failure in association to the antimicrobial regimen
used.
This  is a cohort study conducted at Hospital das Clínicas of
Universidade Federal de Minas Gerais (HC/UFMG), from Febru-
ary  to August 2006, under the Ethics Committee approval: ETIC
273/09 – UFMG.
Patients with neutropenia and antimicrobial (ATM) agents
used  for the treatment of Healthcare Associated Infections
(HAI)  notiﬁed by the Hospital Infection Control Committee
(HICC) were  included. Neutropenia was  deﬁned as neutrophil
counts  ≤500/mm3 or ≤1000/mm3 tending to decline to under
500/mm3 within two days.8
Exclusion criteria were deﬁned as follows: patients younger
than  four years (considering difference in renal function
related to age and different parameters for assessment of
creatinine  clearance), patients without sequential creatinine
measurements suitable for analysis, and patients with high
levels  of baseline creatinine, according to the established crite-
ria.
Renal  insufﬁciency (RI) was  deﬁned when: (a) creatinine
increased two times above baseline; (b) creatinine was  above
2  mg/dL; or (c) creatinine clearance was  below 50 mL/min; or
(d)  association of these criteria.
Other variables included in the analysis were: age, weight,
underlying disease, hematopoietic stem cells transplantation,
number of antimicrobial agents used; association of antimi-
crobial  agents, and time to renal failure.
Renal function was  monitored periodically with serum cre-
atinine  according to physician indication. Baseline creatinine
was  considered the ﬁrst patient’s serum creatinine measured.
Peak  creatinine was  considered the highest creatinine level
identiﬁed  along patient monitoring.
Data were  analyzed using statistical package Epi-Info
version 3.5.2. Descriptive analysis included frequency and per-
centage,  mean or median and standard deviation or range. In
the comparative analysis, the 2 test, Student’s t-test or the
Mann–Whitney U-test were  used, according to studied vari-
ables.  Statistical signiﬁcance was  deﬁned as p < 0.05. The study
was  approved by the Institutional Review Board (IRB).
A  total of 108 patients were  eligible for the study. However,
36  patients were  excluded. Analysis was  carried out with data
from  72 patients and median age was  33.5 years (minimum
four  and maximum 88 years).
Main underlying disease associated with neutropenia was
acute  myeloid leukemia (26/72 = 36.1%), followed by chronic
myelogenous leukemia (18/72 = 25%), acute lymphoblastic
leukemia (10/72 = 19.3%), myelodysplasia (7/72 = 9.7%), lym-
phoma  (6/72 = 8.3) and other malignancies (5/72 = 6.9). 1 3;1  7(4):487–490
Of the 72 patients, 16 (22.2%) underwent allogeneic
hematopoietic stem cells transplantation (HSCT) and 16
(22.2%)  autologous HSCT. In addition, 23 (31.9%) received
nephrotoxic chemotherapy due to underlying disease. There
was  no statistically signiﬁcant association for progression to
renal failure and the use of these drugs (X2 = 1.04 and p = 0.31).
Statistical  association was  also not observed for main nephro-
toxic  drugs used in the chemotherapeutic regimen, such as
cyclosporine,  ifosfamide, cytosin arabinoside e doxorubicin
(X2 = 4.15 and p = 0.38).
Eighteen (25%) patients developed RI: in six (8.3%), cre-
atinine  clearance was  less than 50 mL/min; in ﬁve (6.9%),
creatinine increased two times above baseline; and in only
one  (1.4%) creatinine was  above 2 mg/dL. Six patients had a
combination  of deﬁned criteria for RI. During follow up, only
six  (33.3%) of 18 patients improved renal function to normal
values.
Mean  baseline creatinine was 0.8 mg/dL (SD ± 0.3 mg/dL),
median was  0.8 mg/dL and ranged from 0.1 to 1.3 mg/dL. Mean
creatinine  peak level was 1.2 mg/dL (SD 0.9 mg/dL), median
was  0.9 mg/dL and ranged from 0.2 to 4.5 mg/dL.
There was no signiﬁcant difference when baseline cre-
atinine  and peak creatinine level were  compared in groups
of  different criteria for RI, but there was a tendency for
higher  mean values in patients with a combination of criteria
(p  = 0.09). It should be noted that mean values were  progres-
sively  higher going from criteria 1 to 2 and to 3 (Table 1).
An  average of 3.9 (SD ± 2.3) drugs were used, with a median
of  three drugs, ranging from one to 10 ATM. The majority of
patients  used two (26.4%) or three (29.2%) ATM. When consid-
ering  only ATM with signiﬁcant nephrotoxicity, it was  also
noticed  that great part of patients used two (36.1%) or three
(22.2%)  of them.
As  the patients had several ATM regimens and
due to the small sample size in some groups, it
was  decided to cluster the main groups of ATM
for analysis: ceftazidime + aminoglycoside (n = 21),
ceftazidime + aminoglycoside + vancomycin (n = 9), cef-
tazidime  + aminoglycoside + carbapenem + amphotericin
(n  = 7), and any other association of nephrotoxic ATM (n = 35).
Patients treated with greater number of ATM agents
(ceftazidime + aminoglycoside + vancomycin + carbapenem
+  amphotericin) had more  RI than those who used a different
ATM  regimen, with statistical signiﬁcance (p = 0.024).
When other ATM regimens were excluded and only the
three  most frequent associations of ATM used were  analyzed,
the  difference remained statistically signiﬁcant (p = 0.03),
revealing  that RI was associated with higher number of
ATM.
Considering the median time to progression to IR based
on  any criterion, there was  no statistical difference between
groups  of patients who used different ATM regimens (p = 0.33).
The  median time to progression to RI of the 18 patients who
had  any criterion of IR was 30.7 days (±8.1), with a median
of  22 days, ranging from 4 to 151 days. There was  no differ-
ence  when compared the median time to RI between different
criteria  (p = 0.46), according to Table 2.It was  observed that patients with RI, regardless of the crite-
ria,  were  more  likely to progress to death (<0.001). Among
patients with renal insufﬁciency (n = 18), 50% died during
b r a z j i n f e c t d i s . 2 0 1 3;1 7(4):487–490  489
Table 1 – Evaluation of baseline and peak creatinine (mg/dL) levels among neutropenic patients with different criteria for
renal failure. HC/UFMG, 2006.
Creatinine Renal insufﬁciency criteria n Mean DP ANOVA p
Basal 1. Creatinine increased two times above baseline level OR creatinine above 2 mg/dL 6 0.8 0.4 0.64 0.54
2. Creatinine clearance below 50 mL/min 6 0.8 0.2
3. Criteria combination 6 1.0 0.2
Peak 1. Creatinine increased two times above baseline level OR creatinine above 2 mg/dL 6  1.5 0.7 2.81 0.9
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ollow-up, percentage signiﬁcantly higher than the 5.6% mor-
ality  of patients without impaired renal function. Patients
ho  died had a mean age of 40.4 years (SD 25.4 years), whereas
he  mean age among survivors was  30.3 years (SD 20.4 years),
ifference  not signiﬁcant (p = 0.12).
The  cause of death was  evaluated: eight patients died with
epsis  (six with impaired renal function); two with respira-
ory  insufﬁciency and one with brain death (all of them with
mpaired  renal function), and just one associated to multiple
rgan  failure (without renal impairment during study). Statis-
ical  analysis showed no association between cause of death
nd  renal impairment (X2 = 4.00 and p = 0.26).
Co-morbidities were also evaluated in order to iden-
ify  other causes of RI. Nine patients had co-morbidities
hypertension = 4; diabetes mellitus = 2 and association with
ypertension  and diabetes mellitus = 3), only one patient with
iabetes  mellitus had impaired renal function and there was no
tatistical difference between groups (X2 = 3.13 and p = 0.37).
The  majority of patients in this study (approximately 93%)
ad  a hematological malignancy as underlying disease. This
nformation  reﬂects the proﬁle of patients assisted in the
ospital,  which is a reference for hematology in the state of
inas  Gerais. It also reafﬁrms the literature, showing that neu-
ropenia  is a more  frequent complication in the treatment of
ematological  than solid tumors.9 Another important ﬁnding
s  that 44.4% of the patients in this study underwent bone mar-
ow  transplantation, which may  reﬂect the severity of studied
ample.
Most  patients (75%) maintained preserved renal func-
ion,  but 25% had RI, which was  detected by different
riteria or their combination. A study, performed by Zager
t  al.,10 that included 272 patients with hematologic malig-
ancies who  underwent hematopoietic cell transplantation
ith myeloablative drugs (89% allogeneic transplantation and
1%  autologous transplantation) revealed that 53% of patients
eveloped  acute kidney injury deﬁned as creatinine increase
wo  times above baseline level.
Values of basal and peak creatinine did not differ sta-
istically in groups of different criteria for RI. This suggests
Table 2 – Median time for progressing (days) to renal failure acc
HC/UFMG, 2006.
Renal insufﬁciency criteria n Mean ±
1. Creatinine increased two times above baseline
level OR creatinine above 2 mg/dL
6 29 ± 1
2. Creatinine clearance below 50 mL/min 6 29 ± 1
3. Criteria combination 6 22 ± 46  2.3 1.3
6 2.9 0.9
that there was  no better criterion of RI for monitoring renal
function  of neutropenic in this sample. However, there was
a  trend for higher mean creatinine level in patients with a
combination  of criteria in the analysis of baseline and peak
creatinine. That may  reﬂect a greater severity in patients who
have  a combination of criteria. One should also be aware that
the  small sample size might have compromised this analy-
sis.
Another  ﬁnding was the association of ATM and higher pro-
portion  of RI. No analysis was  performed to identify if this
difference was  associated to nephrotoxic drugs (potentiated
by  ATM association) or if patients who need more  drugs and
were  more  severely ill tended to have higher risk of progres-
sion  to complications.3 The literature shows that combination
of  nephrotoxic drugs is an independent risk factor for RI, as
observed  in the study by Oliveira et al.,11 a retrospective cohort
analysis  of patients admitted to a clinical–surgical ICU (24
beds)  in a tertiary-care university hospital over a period of
three  consecutive years.
There was  no difference in median time to onset of renal
failure  associated to the ATM regimen used. It is important to
say that ATM grouped to perform the analysis were  not nec-
essarily  administered simultaneously, and patients may  have
used  these drugs at different time points during their hos-
pitalization or in sequential therapy for treatment of febrile
neutropenia, according to international guidelines.3
Considering renal failure criteria, mean of 30.7 days for
the  onset of the RI was  observed. In the study by Zager
et  al.,10 in which patients undergoing hematopoietic stem cell
transplantation and myeloablative drugs were  retrospectively
analyzed, this time was 14 days. Lopes and Jorge, in 2011,12
analyzed several studies on the incidence and risk factors for
acute  kidney injury in patients undergoing transplantation,
but not myeloablative used drugs. The authors observed that
RI  started later, ranging from 22 to 60 days. In the present
study, there was  no statistical difference between criteria for
RI  and onset of kidney damage. This ﬁnding may  reinforce the
idea  that there is no superior criterium for monitoring renal
function  in neutropenic patients.
ording to three different criteria in neutropenic patients.
 DP Median Range Kruskal–Wallis p
4 31 8–47 1.54 0.46
4 8.5 4–151
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Mortality among neutropenic patients who developed
renal failure was  signiﬁcantly higher than among those who
preserved  the renal function. Several studies have docu-
mented  an increase in mortality in patients who develop RI
after  myeloablative and not mieloablative therapy, including
short-  and long-term mortality.12 In the study by Kersting
et  al.,13 no difference was  observed in mortality among those
who  developed and not developed any criteria for RI (p = 0.002).
It  was  a retrospective study performed on 363 adult patients
aged  17–57 years submitted to allogeneic myeloablative stem
cell  transplantation. After correction for complications with
a  high mortality, survival of all grades of ARF were compa-
rable,  showing that ARF without co-morbid conditions has a
good prognosis, and ARF with co-morbid conditions has a poor
prognosis. This poor prognosis could be due to the presence
of  co-morbid conditions rather than to development of ARF
itself.  Liu et al.14 described a multicenter, retrospective study
of  acute kidney injury in adult patients with nonmyeloab-
lative hematopoietic stem cell transplantation. The patients
with  acute kidney injury (AKI) had more  than fourfold higher
odds  of mortality. The odds of mortality in AKI patients were
still  higher (3.3-fold), even when adjusted for other variables,
although it did not reach statistical signiﬁcance (p = 0.054).
The present study did not include an evaluation of risk
factors  for RI. However, it is known that myeloablative treat-
ment  is an independent risk factor for RI, as demonstrated
by Parikh et al.15 on a retrospective cohort study from 1997
to  2003 comparing 140 myeloablative and 129 nonmyeloab-
lative patients, and the association of nephrotoxic drugs, as
discussed before.11
Although no statistical difference between distinct criteria
for  RI, association of greater number of antimicrobials deter-
mines  renal impairment. It was  also observed that the time
required  for RI was  independent of the antimicrobial regimen
used,  but mortality among patients with RI were  higher when
compared  with those who had preserved renal function. It
is  necessary to emphasize the importance of preservation of
renal  function, avoiding association of nephotoxic ATM when
possible,  implying in consequent reduction in morbidity and
mortality  of this group of patients.Conﬂict  of  interest
The authors declare no conﬂict of interest.
1 1 3;1  7(4):487–490
 e  f  e  r  e  n  c  e  s
1. Antoniadou A, Giamarellou H. Fever of unknown origin in
febrile  leukopenia. Infect Dis Clin N Am.  2007;21:1055–90.
2. Friese CR. Chemotherapy-induced neutropenia: important
new  data to guide nursing assessment and management.
Cancer Ther Support Care. 2006;4:21–5.
3.  Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice
guideline for the use of antimicrobial agents in neutropenic
patients with cancer: 2010 update by the Infectious Diseases
Society  of America. Clin Infect Dis. 2011;52:56–93.
4.  Gleckman RA, Czachor JS. Antibiotic side effects. Semin
Respir Crit Care Med. 2000;21.
5.  Gabay M, Tanzy M. Guideline for the management of febrile
neutropenia; 2010. p. 1–9.
6.  Chertow GM, Soroko SH, Paganini EP. Mortality after acute
renal  failure: models for prognostic stratiﬁcation and risk
adjustment. Kidney Int. 2006;70:1120–6.
7.  United States Renal Data System 2009 annual data report:
atlas  of chronic kidney disease and end-stage renal disease in
the United States. Bethesda, MD: National Institutes of
Health,  National Institute of Diabetes and Digestive and
Kidney  Diseases; 2009.
8.  Basu SK, Fernandez ID, Fisher SG, Asselin BL, Lyman GH.
Length  of stay and mortality associated with febrile. J Clin
Oncol.  2005;23:7958–66.
9. Al-Ahwal MS, Al-Sayws F, Johar I. Febrile neutropenia
comparison between solid tumours and hematological
malignancies. Pan Arab Med. 2005;2:4–7.
0.  Zager RA, O’Quigley J, Zager BK, et al. Acute renal failure
following bone marrow transplantation: a retrospective study
of  272 patients. Am J Kidney Dis. 1989;13:210–6.
1.  Oliveira JFP, Silva CA, Barbieri CD, et al. Prevalence and risk
factors  for aminoglycoside nephrotoxicity in intensive care
units.  Antimicrob Agents Chemother. 2009;53:2887–9.
2. Lopes JA, Jorge S. Acute kidney injury following HCT:
incidence, risk factors and outcome. Bone Marrow
Transplant. 2011;46:1399–408.
3. Kersting S, Koomans HA, Hené RJ, Verdonck LF. Acute renal
failure  after allogeneic myeloablative stem cell
transplantation: retrospective analysis of incidence, risk
factors  and survival. Bone Marrow Transplant. 2007;39:
359–65.
4. Liu H, Li Y-F, Liu B-C. A multicenter, retrospective study of
acute  kidney injury in adult patients with nonmyeloablative
hematopoietic SCT. Bone Marrow Transplant. 2010;45:
153–8.
5. Parikh CR, Schrier RW, Storer B, et al. Comparison of ARF after
myeloablative and nonmyeloablative hematopoietic cell
transplantation. Am J Kidney Dis. 2005;45:502–9.
